Compare Novo Nordisk A/S (NVO) vs Shopify Inc. (SHOP) Price & Performance

Novo Nordisk A/STrade

Shopify Inc.Trade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Shopify Inc. — how do they compare? Novo Nordisk A/S trades at $46.39 (market cap $207.85B), while Shopify Inc. trades at $150.25 (market cap $196.35B). The key difference: Novo Nordisk A/S and Shopify Inc. are close in size by market cap, and Novo Nordisk A/S pays a 3.81% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals.

	NVO	SHOP
Market Cap	$207.85B	$196.35B
Sector	Health	Technology
52-Week High	$63.98	$179.01
52-Week Low	$35.29	$95.40
Enterprise Value	$222.55B	$191.59B
Dividend Yield	3.81%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Shopify Inc.

Shopify (SHOP) trades at $149.19, down 3.86% over 24 hours, but maintains a bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates with 30%+ GMV growth, while revenue reached $11.56 billion in 2025. Analyst sentiment is overwhelmingly positive, with 65.6% recommending Buy and a consensus price target of $166.39.

Outlook remains favorable driven by AI commerce integration and expanding payments, but high valuation multiples (P/E 103.11) pose risks if growth slows. Key supports include operational cash flow growth to $2.03 billion in 2025, though competition and macroeconomic pressures require monitoring for sustained upside.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk CEO says GLP-1 drugs for obesity have huge growth potential and economic benefits aheadFox Business · 9 hours agoBullish Novo Nordisk stays a Buy with strong obesity drug lead and improved 2026 outlook despite near-term challenges.Seeking Alpha · 11 hours agoBullish Novo Nordisk faces sell rating amid rising competition and operational challenges, with price target cut to $47.Alex Lavoie · 12 hours agoBearish View details →

SHOP

Shopify downgraded to Hold despite strong growth due to high valuation and insider selling risksSeeking Alpha · 12 hours agoNeutral Sea Limited shares jump 13.8% after strong Q1 revenue growth and reinvestment strategy24/7 Wall Street · 1 day agoBullish Shopify posts strong Q2 growth with AI boosting merchant solutions and marginsSeeking Alpha · 3 days agoBullish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Shopify Inc.

Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.